Preview clinical trial results for an immune-evasive cell therapy targeting type 1 diabetes and potential regenerative medicine implications.
Key Takeaways
- Engineered insulin-producing cells survived and produced insulin for 14 months without immunosuppression
- C-peptide increased with improved glucose control, showing dynamic insulin secretion by the graft
- Cells were implanted into forearm muscle and remained detectable after twelve months